The ERBB network facilitates KRAS-driven lung tumorigenesis

Björn Kruspig, Tiziana Monteverde, Sarah Neidler, Andreas Hock, Emma Kerr, Colin Nixon, William Clark, Ann Hedley, Sarah Laing, Seth B Coffelt, John Le Quesne, Craig Dick, Karen Vousden, Carla P Martins, Daniel J Murphy

Research output: Contribution to journalArticlepeer-review

38 Citations (Scopus)

Abstract

KRAS is the most frequently mutated driver oncogene in human adenocarcinoma of the lung. There are presently no clinically proven strategies for treatment of KRAS-driven lung cancer. Activating mutations in KRAS are thought to confer independence from upstream signaling; however, recent data suggest that this independence may not be absolute. We show that initiation and progression of KRAS-driven lung tumors require input from ERBB family receptor tyrosine kinases (RTKs): Multiple ERBB RTKs are expressed and active from the earliest stages of KRAS-driven lung tumor development, and treatment with a multi-ERBB inhibitor suppresses formation of KRASG12D-driven lung tumors. We present evidence that ERBB activity amplifies signaling through the core RAS pathway, supporting proliferation of KRAS-mutant tumor cells in culture and progression to invasive disease in vivo. Brief pharmacological inhibition of the ERBB network enhances the therapeutic benefit of MEK (mitogen-activated protein kinase kinase) inhibition in an autochthonous tumor setting. Our data suggest that lung cancer patients with KRAS-driven disease may benefit from inclusion of multi-ERBB inhibitors in rationally designed treatment strategies.

Original languageEnglish
JournalScience Translational Medicine
Volume10
Issue number446
DOIs
Publication statusPublished - 20 Jun 2018
Externally publishedYes

Fingerprint

Dive into the research topics of 'The ERBB network facilitates KRAS-driven lung tumorigenesis'. Together they form a unique fingerprint.

Cite this